Hope Meets Caution In Sickle-Cell Disease: Pfizer's Setback And Emerging Breakthroughs
From Oxbryta's suspension to Casgevy and Lyfgenia's approval, sickle-cell disease stands between caution and hope.
(Forbes, 2025-10-20T13:07:31Z)